Sponsor Dossier
Evaris Pharma
Sponsor Dossier for Evaris Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: BURN
- Brand: CALCIUM
- Brand: CHLORHEXIDINE
- Brand: DeBug
- Brand: HYDROGEN
- Brand: HYGI-PREP
- Brand: LIDOCAINE
- Brand: MUCOSOOTHE
- Device (sponsor): Applicator, vaginal, single use
- Device (sponsor): Cavity-wound management dressing
- Device (sponsor): Skin semi-occlusive dressing
- Device (sponsor): Skin semi-occlusive dressing
- Device (sponsor): General-body orifice lubricant, sterile
- Device (sponsor): General-body orifice lubricant, sterile
- Device (sponsor): Organ preservation solution
- Device (sponsor): Lubricant, <specify>
About
Evaris Pharma is an Australian Private Company with ABN 56009293136, registered in Western Australia and currently active. The company operates under the business name Evaris Pharma, which has been in effect since November 2024.
Portfolio
Evaris Pharma holds 15 brands on the ARTG, of which 2 are indexable brands that have cleared the SEO quality gate. The portfolio includes 2 brands with Product Information on file, 1 brand with at least one PBS-listed item, and 1 brand with PBAC outcome(s) on record. Notable brands include BURN, CALCIUM, CHLORHEXIDINE, DeBug, HYDROGEN, HYGI-PREP, LIDOCAINE, MUCOSOOTHE, OBSTETRIC CARE, ORION, ORIPRO and PERRIGO.
Therapeutic focus —
Infectious Disease (6 brands) — Dermatology (2 brands) — Reproductive Health (2 brands) — Pain Management (2 brands) — Neurology (1 brand) — Women's Health (1 brand) — Gastroenterology (1 brand)
PBS footprint
One brand in the Evaris Pharma portfolio is PBS-listed, with the latest PBS schedule date touched on 1 May 2026.
Regulatory activity
The most recent PBAC outcome for Evaris Pharma was recorded on 1 July 2024, with 1 brand holding PBAC outcome(s) on record.